John Creasy, MD
Cancer patients are brave and resilient as they face life-altering decisions regarding surgery and treatment. As a surgical oncologist, I see the opportunity to be a skilled professional and a humble, compassionate, patient-centered physician. I strive to provide an accurate and realistic prognosis with a tone of caring and hope.
Dr. Creasy became a surgical oncologist so he could help patients gain insight into their disease, provide exceptional surgical care, and walk with them during a difficult and vulnerable time.
Dr. Creasy completed his residency in general surgery at Weill Cornell Medicine- New York Presbyterian Hospital in New York, NY. He received additional fellowship training in Surgical Oncology and Hepatopancreatobiliary (HPB) surgery at Duke University in Durham, North Carolina. During that time, he gained broad exposure to oncologic procedures and principles and multi-disciplinary care of cancer patients. That experience, combined with understanding the patient’s unique goals and priorities, facilitates his ability to integrate and manage all components of a patient’s cancer care. Dr. Creasy also gained specialized training in HPB diseases and minimally invasive and robotic surgery, which are his areas of clinical and research interest.
Dr. Creasy enjoys listening to patients and learning about their background and experiences. He seeks to partner with patients and their families to develop treatment plans that align with their goals. He is particularly thankful for the relationship that develops between a surgeon and patient over multiple visits and years. He believes multi-disciplinary patient care requires camaraderie and mutual respect with colleagues and other specialties. As a surgeon at The Oregon Clinic, Dr. Creasy has the privilege to work alongside a team of caring and talented support staff to provide an excellent experience, personalized care, and the best outcomes for patients. He is also honored to be involved with education in the fellowship training of young surgeons.
As a transplant to the Pacific Northwest, Dr. Creasy and his family are excited to live in Portland and combine a culturally robust city with the awe-inspiring natural beauty of Oregon. He is thankful that Portland offers great neighborhoods, local restaurants and breweries, and accessibility to nearby forests and national parks. Outside of the hospital, Dr. Creasy enjoys hiking and camping with his wife and three children. He also likes reading, history, barbecue, college football, and his kids’ sports teams.
- Fellow, Complex General Surgical Oncology and HPB Surgery, Duke University Medical Center, Durham, NC, 2021
- Resident, General Surgery, Weill Cornell Medicine, New York Presbyterian Hospital, New York, NY, 2019
- Research Fellow, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, 2016-2017
- MD, Wake Forest School of Medicine, Winston, Salem, NC 2012
- BA, University of North Carolina- Chapel Hill, Chapel Hill, NC 2007
- Alpha Omega Alpha (Wake Forest School of Medicine)
- Third Year Medical Student Clerkship Teaching Award (2016, Weill Cornell Medical College)
- Best Clinical Presentation Award (2017 Resident Research Symposium, New York Presbyterian Hospital, Department of Surgery)
- Fabrizio Michelassi Chief Surgical Resident Award (2019, New York Presbyterian Hospital)
- Creasy JM, Napier KJ, Reed SA, Zani S, Wong TZ, Kim CY, Wildman-Tobriner B, Strickler JH, Hsu SD, Uronis HE, Allen PJ, Lidsky ME. Implementation of a hepatic artery infusion program: initial patient selection and perioperative outcomes of concurrent hepatic artery infusions and systemic chemotherapy for colorectal liver metastases. Ann Surg Oncol 2020; 27 (13): 5068-5095.
- Buisman FE, van der Stok EP, Galjart B, Vermeulen PB, Balachandran VP, Coebergh van den Braak RRJ, Creasy JM, Hoppener DJ, Jarnagin WR, Kingham TP, Nierop PMH, Sadot E, Shia J, Koerkamp BG, Grunhagen DJ, D’Angelica MI, Verhoef C. Histopathological growth patterns as biomarker for adjuvant systemic chemotherapy in patients with resected colorectal liver metastases. Clin Exp Metastasis 2020; 37 (5):593-605.
- Creasy JM, Goldman DA, Gonen M, Dudeja V, O’Reilly EM, Abou-Alfa GK, Cercek A, Harding JJ, Balachandran VP, Drebin JA, Allen PJ, Kingham TP, D’Angelica MI, Jarnagin WR. Evolution of surgical management of gallbladder carcinoma and impact on outcome: results from two decades at a single-institution. HPB (Oxford) 2019; 21 (11): 1541-1551.
- Narayan RR, Creasy JM, Goldman DA, Gonen M, Kandoth C, Kundra R, Solit DB, Askan G, Klimstra DS, Basturk O, Allen PJ, Balachandran VP, D’Angelica MI, DeMatteo RP, Drebin JA, Kingham TP, Simpson AL, Abou-Alfa GK, Harding JJ, O’Reilly EM, Butte JM, Matsuyama R, Endo I, Jarnagin WR. Regional differences in gallbladder cancer pathogenesis: Insights from a multi-institutional comparison of tumor mutations. Cancer 2019; 125(4):575-585.
- Creasy JM, Midya A, Chakraborty J, Adam LB, Gomes C, Seastedt KP, Sutton EJ, Cercek A, Kemeny NE, Shia J, Balachandran VP, Kingham TP, Allen PJ, DeMatteo RP, Jarnagin WR, D’Angelica MI, Do RKG, Simpson AL. Quantitative imaging features of pretreatment CT predict volumetric response to chemotherapy in patients with colorectal liver metastases. Eur Radiol 2019; 29(1):458-467.
- Creasy JM, Sadot E, Koerkamp BG, Chou JF, Gonen M, Kemeny NE, Saltz LB, Balachandran VP, Kingham TP, DeMatteo RP, Allen PJ, Jarnagin WR, D’Angelica MI. The Impact of Primary Tumor Location on Long-Term Survival in Patients Undergoing Hepatic Resection for Metastatic Colon Cancer. Ann Surg Oncol 2018; 25(2):431-438.
- Creasy JM, Sadot E, Koerkamp BG, Chou JF, Gonen M, Kemeny NE, Balachandran VP, Kingham TP, DeMatteo RP, Allen PJ, Blumgart LH, Jarnagin WR, D’Angelica MI. Actual 10-year survival after hepatic resection of colorectal liver metastases: what factors preclude cure? Surgery 2018; 163(6):1238-1244.
- Creasy JM, Goldman DA, Gonen M, Dudeja V, Askan G, Basturk O, Balachandran VP, Allen PJ, DeMatteo RP, D’Angelica MI, Jarnagin WR. Predicting Residual Disease in Incidental Gallbladder Cancer: Risk Stratification for Modified Treatment Strategies. J Gastrointest Surg 2017; 21(8):1254-1261.
- Simpson AL, Doussot A, Creasy JM, Adam LB, Allen PJ, DeMatteo RP, Gonen M, Kemeny NE, Kingham TP, Shia J, Jarnagin WR, Do RKG, D’Angelica MI. Computed Tomography Image Texture: A Noninvasive Prognostic Marker of Hepatic Recurrence After Hepatectomy for Metastatic Colorectal Cancer. Ann Surg Oncol 2017; 24(9):2482-2490.
- Creasy JM, Goldman DA, Dudeja V, Lowery MA, Cercek A, Balachandran VP, Allen PJ, DeMatteo RP, Kingham TP, D’Angelica MI, Jarnagin WR. Systemic Chemotherapy Combined with Resection for Locally Advanced Gallbladder Carcinoma: Surgical and Survival Outcomes. J Am Coll Surg 2017; 224(5):906-916.
- Member, Society of Surgical Oncology
- Members, Americas Hepato-Pancreato-Biliary Association (AHPBA)